LA ROCHE-POSAY

Main information

  • Trade name:
  • LA ROCHE-POSAY LABORATOIRE DERMATOLOGIQUE UVIDEA XL DAILY PROTECTION MELT IN CREAM SPF50
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • LA ROCHE-POSAY LABORATOIRE DERMATOLOGIQUE UVIDEA XL DAILY PROTECTION MELT IN CREAM SPF50
    Australia
  • Language:
  • English

Other information

Status

  • Source:
  • Dept. of Health,Therapeutic Goods Administration - Australia
  • Authorization number:
  • 221574
  • Last update:
  • 08-10-2017

Public Assessment Report

Public Summary

Summary for ARTG Entry:

221574

LA ROCHE-POSAY LABORATOIRE DERMATOLOGIQUE UVIDEA XL DAILY PROTECTION MELT IN

CREAM SPF50

ARTG entry for

Medicine Listed

Sponsor

L'Oreal Australia Pty Ltd

Postal Address

PO Box 6813,ST KILDA ROAD CENTRAL, VIC, 3004

Australia

ARTG Start Date

24/03/2014

Product category

Medicine

Status

Active

Approval area

Listed Medicines

Conditions

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine,

(b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is

sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be

kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records

to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted

in relation to the inclusion of the medicine in the Register.

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office

of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors

of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified

of the report or reports.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine

outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National

Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1. LA ROCHE-POSAY LABORATOIRE DERMATOLOGIQUE UVIDEA XL DAILY PROTECTION MELT IN CREAM

SPF50

Product Type

Single Medicine Product

Effective date

24/03/2014

Warnings

Contains ethanol. (or words to that effect).

Contains phenoxyethanol (or words to that effect).

Avoid prolonged exposure in the sun.[or words to that effect]

Wear protective clothing, hats and eyewear when exposed to the sun.[Or words to this effect]

Avoid contact with eyes (or words to that effect).

Standard Indications

A broad spectrum sunscreening preparation of SPF50. Can aid in the prevention of sunspots

Broad Spectrum Sunscreen

A broad spectrum sunscreening preparation of SPF4 or greater. Can aid in the prevention of premature skin ageing.

A broad spectrum sunscreening preparation of SPF50. May reduce the risk of some skin cancers

A broad spectrum sunscreening preparation of SPF50. May assist in preventing some skin cancers

A broad spectrum sunscreening preparation of SPF50. Can aid in the prevention of solar keratoses

Sunscreen SPF50

Specific Indications

High Protection Broad Spectrum Sunscreen.

High Protection Sunscreen,

UVB/UVA Broad Spectrum,

Against Harmful UV Rays

Non Comedogenic.

Hypoallergenic.

SPF50.

Long UVA rays account for more than 75% of UVA rays.

The formula contains anti UVA filtering system.

Skin is protected from UVA induced dark spots, fine lines, irregular and sagging skin texture

Additional Product information

Public Summary

Page 1 of

Produced at 24.11.2017 at 02:12:25 AEDT

This is not an ARTG Certificate document.

The onus is on the reader to verify the current accuracy of the information on the document subsequent to the date shown.

Visit www.tga.gov.au for contact information

Pack Size/Poison information

Pack Size

Poison Schedule

Components

1. Formulation 1

Dosage Form

Cream

Route of Administration

Topical

Visual Identification

Active Ingredients

bemotrizinol

15 mg/g

diethylamino hydroxybenzoyl hexyl benzoate

20 mg/g

Drometrizole trisiloxane

60 mg/g

Ecamsule

24.75 mg/g

octyl methoxycinnamate

70.929 mg/g

titanium dioxide

33.2 mg/g

© Commonwealth of Australia.This work is copyright.You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior

written approval from the Commonwealth.Further details can be found at http://www.tga.gov.au/about/website-copyright.htm.

Public Summary

Page 2 of

Produced at 24.11.2017 at 02:12:25 AEDT

This is not an ARTG Certificate document.

The onus is on the reader to verify the current accuracy of the information on the document subsequent to the date shown.

Visit www.tga.gov.au for contact information